Galectin Therapeutics Future Growth
Future criteria checks 0/6
Galectin Therapeutics is forecast to grow earnings and revenue by 54.5% and 60.8% per annum respectively while EPS is expected to grow by 48.8% per annum.
Key information
54.5%
Earnings growth rate
48.8%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 60.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 01 Apr 2024 |
Recent future growth updates
Recent updates
Galectin rises as FDA approves to begin human trial of combination immunotherapy in head and neck cancer
Oct 12Galectin Therapeutics GAAP EPS of -$0.16
Aug 15Galectin: Ability To Potentially Target Unmet Medical Need
Jul 11Galectin: Pursuing A Subset In The NASH Space
Jul 01Read This Before Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares
Feb 25
Is Galectin Therapeutics (NASDAQ:GALT) In A Good Position To Deliver On Growth Plans?
Jan 21How Much Of Galectin Therapeutics, Inc. (NASDAQ:GALT) Do Insiders Own?
Dec 09Galectin Therapeutics reports Q3 results
Nov 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 180 | -63 | N/A | N/A | 1 |
| 12/31/2025 | 36 | -101 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -41 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -45 | -33 | -33 | N/A |
| 9/30/2023 | N/A | -45 | -36 | -36 | N/A |
| 6/30/2023 | N/A | -40 | -36 | -36 | N/A |
| 3/31/2023 | N/A | -40 | -34 | -34 | N/A |
| 12/31/2022 | N/A | -39 | -31 | -31 | N/A |
| 9/30/2022 | N/A | -35 | -31 | -31 | N/A |
| 6/30/2022 | N/A | -35 | -27 | -27 | N/A |
| 3/31/2022 | N/A | -34 | -26 | -26 | N/A |
| 12/31/2021 | N/A | -31 | -24 | -24 | N/A |
| 9/30/2021 | N/A | -31 | -23 | -23 | N/A |
| 6/30/2021 | N/A | -29 | -26 | -26 | N/A |
| 3/31/2021 | N/A | -26 | -23 | -23 | N/A |
| 12/31/2020 | N/A | -24 | -21 | -21 | N/A |
| 9/30/2020 | N/A | -21 | -19 | -19 | N/A |
| 6/30/2020 | N/A | -18 | -12 | -12 | N/A |
| 3/31/2020 | N/A | -15 | -12 | -12 | N/A |
| 12/31/2019 | N/A | -20 | -11 | -11 | N/A |
| 9/30/2019 | N/A | -18 | -9 | -9 | N/A |
| 6/30/2019 | N/A | -19 | -9 | -9 | N/A |
| 3/31/2019 | N/A | -20 | -10 | -10 | N/A |
| 12/31/2018 | N/A | -15 | -10 | -10 | N/A |
| 9/30/2018 | N/A | -14 | -12 | -12 | N/A |
| 6/30/2018 | N/A | -16 | -14 | -14 | N/A |
| 3/31/2018 | N/A | -17 | -16 | -16 | N/A |
| 12/31/2017 | N/A | -17 | -16 | -16 | N/A |
| 9/30/2017 | N/A | -20 | N/A | -17 | N/A |
| 6/30/2017 | N/A | -20 | N/A | -17 | N/A |
| 3/31/2017 | N/A | -21 | N/A | -17 | N/A |
| 12/31/2016 | N/A | -22 | N/A | -16 | N/A |
| 9/30/2016 | N/A | -22 | N/A | -16 | N/A |
| 6/30/2016 | N/A | -24 | N/A | -18 | N/A |
| 3/31/2016 | N/A | -23 | N/A | -16 | N/A |
| 12/31/2015 | N/A | -21 | N/A | -17 | N/A |
| 9/30/2015 | N/A | -20 | N/A | -15 | N/A |
| 6/30/2015 | N/A | -18 | N/A | -14 | N/A |
| 3/31/2015 | N/A | -17 | N/A | -13 | N/A |
| 12/31/2014 | N/A | -17 | N/A | -12 | N/A |
| 9/30/2014 | N/A | -16 | N/A | -11 | N/A |
| 6/30/2014 | N/A | -16 | N/A | -9 | N/A |
| 3/31/2014 | N/A | -24 | N/A | -9 | N/A |
| 12/31/2013 | N/A | -22 | N/A | -7 | N/A |
| 9/30/2013 | N/A | -22 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GALT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GALT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GALT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GALT is forecast to have no revenue next year.
High Growth Revenue: GALT is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GALT's Return on Equity is forecast to be high in 3 years time